These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9248959)

  • 41. [Systematic therapy of vaginal mycoses. Three quarters of women are affected].
    Gynakologe; 1994 Jun; 27(3 Suppl):1-4. PubMed ID: 9211662
    [No Abstract]   [Full Text] [Related]  

  • 42. Antifungal susceptibility testing: a primer for clinicians.
    Kuper KM; Coyle EA; Wanger A
    Pharmacotherapy; 2012 Dec; 32(12):1112-22. PubMed ID: 23165897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Globoroseomycin, a new antifungal antibiotic.
    Yukun L; Yingyuan Z; Zhiling Z; Meifang Z; Ziying D; Tiancai L; Jiezhi F; Jinji H
    Chin Med J (Engl); 1979 Jul; 92(7):443-50. PubMed ID: 114368
    [No Abstract]   [Full Text] [Related]  

  • 44. Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine.
    Hood SV; Moore CB; Cheesbrough JS; Mene A; Denning DW
    Br J Dermatol; 1997 Jun; 136(6):953-6. PubMed ID: 9217835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antifungal susceptibility testing. New technology and clinical applications.
    Pfaller MA; Yu WL
    Infect Dis Clin North Am; 2001 Dec; 15(4):1227-61. PubMed ID: 11780273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluconazole and itraconazole: current status and prospects for antifungal therapy.
    Sugar AM
    Curr Clin Top Infect Dis; 1993; 13():74-98. PubMed ID: 8397919
    [No Abstract]   [Full Text] [Related]  

  • 47. High-dose fluconazole therapy in patients with severe fungal infections.
    Voss A; de Pauw BE
    Eur J Clin Microbiol Infect Dis; 1999 Mar; 18(3):165-74. PubMed ID: 10357048
    [No Abstract]   [Full Text] [Related]  

  • 48. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.
    Ghannoum MA; Rex JH; Galgiani JN
    J Clin Microbiol; 1996 Mar; 34(3):489-95. PubMed ID: 8904400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of antifungal susceptibility testing in the management of patients with invasive mycoses.
    Perea S; Patterson TF
    Rev Iberoam Micol; 1999 Dec; 16(4):180-6. PubMed ID: 18473544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The evolving role of antifungal susceptibility testing.
    Eschenauer GA; Carver PL
    Pharmacotherapy; 2013 May; 33(5):465-75. PubMed ID: 23553342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiology of antifungal susceptibility: Review of literature.
    Hadrich I; Ayadi A
    J Mycol Med; 2018 Sep; 28(3):574-584. PubMed ID: 29773435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Choice and use of the new antifungal agents].
    Meyer RD
    Rev Clin Esp; 1994 Feb; 194(2):116-27. PubMed ID: 8008935
    [No Abstract]   [Full Text] [Related]  

  • 53. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.
    Albataineh MT; Sutton DA; Fothergill AW; Wiederhold NP
    Infect Dis Clin North Am; 2016 Mar; 30(1):13-35. PubMed ID: 26739605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antifungal susceptibility testing. Current state of technology, limitations, and standardization.
    Pfaller MA; Rinaldi MG
    Infect Dis Clin North Am; 1993 Jun; 7(2):435-44. PubMed ID: 8345178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.
    Ostrosky-Zeichner L; Andes D
    J Infect Dis; 2017 Aug; 216(suppl_3):S452-S457. PubMed ID: 28911047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antifungal susceptibility testing.
    Rex JH; Pfaller MA; Rinaldi MG; Polak A; Galgiani JN
    Clin Microbiol Rev; 1993 Oct; 6(4):367-81. PubMed ID: 8269392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients.
    Conti DJ; Tolkoff-Rubin NE; Baker GP; Doran M; Cosimi AB; Delmonico F; Auchincloss H; Russell PS; Rubin RH
    Transplantation; 1989 Oct; 48(4):692-5. PubMed ID: 2552628
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy.
    Kami M; Machida U; Okuzumi K; Matsumura T; Mori Si S; Hori A; Kashima T; Kanda Y; Takaue Y; Sakamaki H; Hirai H; Yoneyama A; Mutou Y
    Br J Haematol; 2002 Apr; 117(1):40-6. PubMed ID: 11918531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The exciting future of antifungal therapy.
    Neely MN; Ghannoum MA
    Eur J Clin Microbiol Infect Dis; 2000 Dec; 19(12):897-914. PubMed ID: 11205627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced fungal specificity and
    Rivera A; Young Lim W; Park E; Dome PA; Hoy MJ; Spasojevic I; Sun S; Averette AF; Pina-Oviedo S; Juvvadi PR; Steinbach WJ; Ciofani M; Hong J; Heitman J
    mBio; 2023 Oct; 14(5):e0181023. PubMed ID: 37737622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.